The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing aemisinin derivative (aemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except:
Aemether plus lumefantrine Aesunate plus quinine Aesunate plus pyrimethamine-sulfadoxine Aesunate plus mefloquine